Coronavirus: Timeline of DOD Support to the National Response

The new administration continues the whole of America approach to the nation’s response to COVID-19 with the National Strategy for the COVID-19 Response and Pandemic Preparedness. Many of the dedicated individuals, along with the agencies and industries who contributed to Operation Warp Speed, continue to support the national response to COVID-19 under the new administration

The Department of Health and Human Services (HHS) and the Department of Defense (DOD) announces the purchase of 1.25 million additional treatment courses of Regeneron’s investigational monoclonal antibody therapeutic to be delivered in the first half of 2021 to treat non-hospitalized, high-risk COVID-19 patients

Army Gen. Gustave F. Perna, chief operating officer of Operation Warp Speed; Dr. Moncef Slaoui, chief advisor to Operation Warp Speed; Secretary of Health and Human Services Alex M. Azar II; and Dr. Robert R. Redfield, Director of the Centers for Disease Control and Prevention brief the news media on Operation Warp Speed

Army Gen. Gustave F. Perna, chief operating officer of Operation Warp Speed; Dr. Moncef Slaoui, chief advisor to Operation Warp Speed; and Health and Human Services Secretary Alex M. Azar II brief the media on the progress of Operation Warp Speed

Army Gen. Gustave F. Perna, chief operating officer of Operation Warp Speed, and Dr. Moncef Slaoui, chief advisor to Operation Warp Speed, brief the media on Operation Warp Speed and COVID-19 vaccine distribution

Novavax begins Phase 3 clinical trials

The U.S. Department of the Health and Human Services and DOD jointly announce an agreement with Merck to continue the development and large-scale manufacturing of investigational COVID-19 treatment MK-7110

The Administration announces that it will purchase an additional 100 million doses of COVID-19 vaccine from Pfizer through the U.S. Department of Health and Human Services and DOD

Army Gen. Gustave F. Perna, chief operating officer of Operation Warp Speed; Dr. Moncef Slaoui, chief advisor to Operation Warp Speed; and Health and Human Services Secretary Alex M. Azar II brief the media on the progress of Operation Warp Speed

Army Gen. Gustave F. Perna, chief operating officer of Operation Warp Speed; Dr. Moncef Slaoui, chief advisor to Operation Warp Speed; and Health and Human Services Secretary Alex M. Azar II brief the media on the progress of Operation Warp Speed

Army Gen. Gustave F. Perna, chief operating officer of Operation Warp Speed, briefs the media on Operation Warp Speed and COVID-19 vaccine distribution

U.S. Food and Drug Administration issues an Emergency Use Authorization for Moderna's COVID-19 vaccine

Army Gen. Gustave F. Perna, chief operating officer of Operation Warp Speed; Dr. Moncef Slaoui, chief advisor to Operation Warp Speed; and Health and Human Services Secretary Alex M. Azar II brief the media on Operation Warp Speed and COVID-19 vaccine distribution

Army Gen. Gustave F. Perna, chief operations officer for Operation Warp Speed; Health and Human Services Secretary Alex M. Azar II; and Dr. Moncef Slaoui, chief advisor for OWS, conduct a briefing on Operation Warp Speed beginning nationwide vaccine distribution

Army Gen. Gustave F. Perna, chief operations officer for Operation Warp Speed, conducts a briefing on Operation Warp Speed planning for nationwide vaccine distribution

DOD purchases an additional 100 million doses of Moderna's COVID-19 vaccine

U.S. Food and Drug Administration issues an Emergency Use Authorization to Pfizer for its COVID-19 vaccine

Army Gen. Gustave F. Perna, chief operations officer for Operation Warp Speed, Health and Human Services Secretary Alex M. Azar II and Dr. Moncef Slaoui, chief advisor for OWS, conduct a briefing on Operation Warp Speed

Congressional/media engagement on Emergency Use Authorization of Regeneron's investigational monoclonal antibody therapeutic cocktail

U.S. Food and Drug Administration issues an Emergency Use Authorization for Regeneron's investigational monoclonal antibody therapeutic cocktail comprised of the drugs casirivimab and imdevimab for treatment of non-hospitalized patients with mild or moderate confirmed cases of COVID-19 at high risk of hospitalization

Army Gen. Gustave F. Perna, chief operations officer for Operation Warp Speed, Health and Human Services Secretary Alex M. Azar II and Dr. Moncef Slaoui, chief advisor for OWS, conduct a briefing on Operation Warp Speed

The U.S. government partnered with large chain pharmacies and networks covering approximately 60 percent of pharmacies throughout the United States, Puerto Rico, and the U.S. Virgin Islands to maximize access to COVID-19 vaccines

Congressional/media engagement on OWS vaccine distribution and therapeutics

U.S. Food and Drug Administration issues an Emergency Use Authorization for Eli Lilly's COVID-19 investigational antibody therapeutic

The Department of Health and Human Services and DOD announce an agreement with Eli Lilly and Company to purchase 300,000 doses of the company's COVID-19 investigational antibody therapeutic for $375 million. These doses will be available for patient care if the U.S. Food and Drug Administration authorizes use of the therapeutic, as outlined in agency guidance

AstraZeneca resumes COVID-19 Phase 3 vaccine clinical trials in the United States after the FDA and an independent safety review board completed an examination of all safety data from trials globally and concluded it was safe to resume

Congressional/media engagement on OWS vaccine distribution and minority enrollment in clinical trials

All 64 jurisdictions submitted initial COVID-19 vaccine distribution plans to the Centers for Disease Control and Prevention, a significant milestone in the ongoing collaboration between the federal government and jurisdictions to prepare for delivery of a safe, effective vaccine to the American people

The Department of Health and Human Services and DOD announce agreements with CVS and Walgreens to provide COVID-19 vaccine with no out-of-pocket costs to protect vulnerable Americans in long-term care facilities nationwide once vaccines are available and recommended for them

$31 million agreement with Cytiva to expand manufacturing capacity for products essential in producing COVID-19 vaccines, such as liquid and dry powder cell culture media, cell culture buffers, mixer bags, and XDR bioreactors

$486 million agreement with AstraZeneca for late-stage development and large-scale manufacturing of the company's COVID-19 investigational prophylaxis product, a cocktail of two monoclonal antibodies, that may help treat or prevent the coronavirus that causes COVID-19

Congressional/media engagement on OWS vaccine distribution

Johnson & Johnson begins Phase 3 clinical trials

The Department of Health and Human Services and DOD release two documents outlining the Administration's strategy to deliver safe and effective COVID-19 vaccine doses to Americans as quickly and reliably as possible. The documents provide a strategic distribution overview along with an interim playbook for jurisdiction operations

Congressional/media engagement on OWS vaccines

AstraZeneca pauses clinical trials due to an unexpected adverse event in a study participant in the Phase 2/3 trial in the UK. AstraZeneca is working with the FDA to facilitate review of the information and the agency will decide when the U.S. trial can resume

As part of the Operation Warp Speed goal to deliver safe and effective vaccines and therapeutics by January 2021, five DOD medical treatment facilities are identified for Phase 3 COVID-19 vaccine trials. The selected sites are located in the National Capital Region, San Antonio and San Diego

AstraZeneca begins Phase 3 clinical trials

Congressional/media engagement on OWS vaccine distribution

U.S. Food and Drug Administration issues an Emergency Use Authorization for convalescent plasma

$106 million contract with Ology Bioservices Inc. to reserve production capacity of more than 180 million doses of COVID-19 medical countermeasures

CDC selects McKesson Corporation to support distribution of COVID-19 vaccines and related supplies

Congressional/media engagement on OWS vaccine prioritization

$1.5 billion agreement with Moderna to support the large-scale manufacture and delivery of a vaccine candidate

$1 billion agreement with Johnson & Johnson (Janssen) to support the large-scale manufacturing and delivery of a vaccine candidate

$160 million awarded to Grand River Aseptic ManufacturingInc. for domestic aseptic fill and finish manufacturing capacity for critical vaccines and therapeutics

$2 billion agreement with Sanofi and GlaxoSmithKline to support the advanced development, including clinical trials and large-scale manufacturing, of a vaccine candidate

Congressional/media engagement on OWS vaccines

Moderna and Pfizer begin Phase 3 clinical trials

Texas A&M University and FUJIFILM announce a task order with Texas A&M University and FUJIFILM to advance domestic manufacturing capabilities and capacity for a potential COVID-19 vaccine

$1.95 billion agreement with Pfizer for the large-scale manufacturing and nationwide distribution of 100 million doses of their vaccine candidate

Congressional/media engagement on OWS vaccines

$1.6 billion agreement to support the large-scale manufacturing of Novavax's vaccine candidate

GEN Gustave Perna is Senate-confirmed to serve as chief operating officer

GEN Gustave Perna confirmation hearing

Congressional/media engagement on OWS vaccines

$143 million agreement with SiO2 Materials Science to ramp up capacity to produce the company's glass-coated plastic container

$204 million agreement with Corning to expand the domestic manufacturing capacity to produce approximately 164 million Valor Glass vials per year

Emergent BioSolutions announces a task order to advance domestic manufacturing capabilities and capacity for a potential COVID-19 vaccine as well as therapeutics

$1.2 billion agreement in support for AstraZeneca's candidate vaccine

White House announces Operation Warp Speed, or OWS

$138 million contract with ApiJect for more than 100 million prefilled syringes for distribution across the United States by year-end

$483 million agreement in support available for Moderna's candidate vaccine, which began Phase 1 trials on March 16, 2020, and received a fast-track designation from the U.S. Food & Drug Administration

$456 million for Johnson & Johnson's candidate vaccine